文献速递乳腺癌

Oncotype DX、Prosigna、EndoPredict与BCI的分子驱动因素:TransATAC研究

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
PubMed 文献 · J Clin Oncol · 2020-10-27

TransATAC研究对785例ER阳性/HER2阴性、未接受化疗的乳腺癌患者分析四种预后检测的分子驱动因素。结果显示RS主要受雌激素模块负向驱动,而ROR、EP和BCI主要由增殖模块驱动,解释了各检测预后性能的差异。

要点

  • RS与雌激素模块强负相关(ρ=-0.79),增殖模块仅中度正相关(ρ=0.36)。
  • ROR、EP和BCI的变异主要由增殖模块解释,分别占72.5%、50.0%和54.3%。
  • 四检测间相关性中等至强(ρ=0.63-0.74),但RS与ROR(ρ=0.32)及RS与BCI(ρ=0.35)相关性弱。

核心结论

  • RS主要由雌激素相关特征决定,增殖标志物作用较弱;而EP、BCI尤其是ROR主要由增殖特征决定,这有助于解释各检测预后性能的差异。

研究设计与样本

  • TransATAC研究纳入ATAC试验中他莫昔芬或阿那曲唑臂的785例ER阳性/HER2阴性、未接受化疗且四种检测均可用的乳腺癌患者。
  • 由制造商对RS、ROR、EP和BCI进行检测分析,比较时排除了部分检测中包含的临床病理特征。
  • 采用Spearman相关和方差分析,以RS的雌激素、增殖、侵袭和HER2模块评分表征相应分子特征。

主要发现

  • 四种分子评分间呈中等至强相关(ρ=0.63-0.74),但RS与ROR(ρ=0.32)及RS与BCI(ρ=0.35)相关性弱。
  • RS与其雌激素模块强负相关(ρ=-0.79),与其增殖模块中度正相关(ρ=0.36)。
  • RS的增殖模块解释了ROR变异的72.5%,而雌激素模块仅解释0.6%。
  • EP和BCI的变异大部分由增殖模块解释(分别为50.0%和54.3%),雌激素模块解释较少(分别为20.2%和2.7%)。

临床怎么用

  • 临床解读RS时应认识到其更多反映雌激素信号而非增殖活性,而ROR、EP和BCI则主要反映增殖特征。
  • 检测间预后估计不一致时,可结合其分子驱动差异理解,避免简单互换使用。

局限性

  • 分析限于TransATAC样本中ER阳性/HER2阴性、未接受化疗且四种检测均可用的785例患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Oncotype DX Recurrence Score (RS), Prosigna Prediction Analysis of Microarray 50 (PAM50) Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI) are used clinically for estimating risk of distant recurrence for patients receiving endocrine therapy. Discordances in estimates occur between them. We aimed to identify the molecular features that drive the tests and lead to these differences. PATIENTS AND METHODS: Analyses for RS, ROR, EP, and BCI were conducted by the manufacturers in the TransATAC sample collection that consisted of the tamoxifen or anastrozole arms of the ATAC trial. Estrogen receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative cases without chemotherapy treatment were included in which all four tests were available (n = 785). Clinicopathologic features included in some tests were excluded from the comparisons. Estrogen, proliferation, invasion, and HER2 module scores from RS were used to characterize the respective molecular features. Spearman correlation and analysis of variance tests were applied. RESULTS: There were moderate to strong correlations among the four molecular scores (ρ = 0.63-0.74) except for RS versus ROR (ρ = 0.32) and RS versus BCI (ρ = 0.35). RS had strong negative correlation with its estrogen module (ρ = -0.79) and moderate positive correlation with its proliferation module (ρ = 0.36). RS's proliferation module explained 72.5% of ROR's variance, while the estrogen module explained only 0.6%. Most of EP's and BCI's variation was accounted for by the proliferation module (50.0% and 54.3%, respectively) and much less by the estrogen module (20.2% and 2.7%, respectively). CONCLUSION: In contrast to common understanding, RSs are determined more strongly by estrogen-related features and only weakly by proliferation markers. However, the EP, BCI, and particularly ROR scores are determined largely by proliferative features. These relationships help to explain the differences in the prognostic performance of the tests.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Buus R, Sestak I, Kronenwett R, et al. Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. J Clin Oncol. 2020. PMID: 33108242. doi:10.1200/JCO.20.00853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。